GAIN THERAPEUTICS, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GAIN THERAPEUTICS, INC (GANX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $352.02 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2024-11-14
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $352.02K, a 58.23% decline year-over-year.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $1.43M, a 3.51% increase year-over-year.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $145.47K, a 74.27% decline year-over-year.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-12-31 was $512.53K, a 8.26% decline year-over-year.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.31M, a 116.52% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.53M, a 81.85% increase from fiscal 2021.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $839.37K, a 928.14% increase from fiscal 2020.
- GAIN THERAPEUTICS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $81.64K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-09-30 | $352.02K 10-Q · filed 2024-11-14 | $1.78M derived: sum of 2 quarters · filed 2024-11-14 | $1.93M 10-Q · filed 2024-11-14 | $2.44M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $1.43M 10-Q · filed 2024-08-08 | $1.58M 10-Q · filed 2024-08-08 | $2.09M derived: sum of 3 quarters · filed 2024-08-08 | $2.93M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $145.47K 10-Q · filed 2024-05-14 | $658.01K derived: sum of 2 quarters · filed 2024-05-14 | $1.50M derived: sum of 3 quarters · filed 2024-11-14 | $2.89M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $512.53K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.36M derived: sum of 2 quarters · filed 2024-11-14 | $2.74M derived: sum of 3 quarters · filed 2024-11-14 | $3.31M 10-K · filed 2024-03-26 |
| 2023-09-30 | $842.82K 10-Q · filed 2024-11-14 | $2.23M derived: sum of 2 quarters · filed 2024-11-14 | $2.79M 10-Q · filed 2024-11-14 | $3.35M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.38M 10-Q · filed 2024-08-08 | $1.95M 10-Q · filed 2024-08-08 | $2.51M derived: sum of 3 quarters · filed 2024-08-08 | $2.86M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $565.43K 10-Q · filed 2024-05-14 | $1.12M derived: sum of 2 quarters · filed 2024-05-14 | $1.48M derived: sum of 3 quarters · filed 2024-05-14 | $1.79M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $558.69K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $914.34K derived: sum of 2 quarters · filed 2024-03-26 | $1.22M derived: sum of 3 quarters · filed 2024-03-26 | $1.53M 10-K · filed 2024-03-26 |
| 2022-09-30 | $355.65K 10-Q · filed 2023-11-14 | $661.20K derived: sum of 2 quarters · filed 2023-11-14 | $967.74K 10-Q · filed 2023-11-14 | $1.25M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $305.55K 10-Q · filed 2023-08-10 | $612.10K 10-Q · filed 2023-08-10 | $898.36K derived: sum of 3 quarters · filed 2023-08-10 | $1.15M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $306.55K 10-Q · filed 2023-05-12 | $592.80K derived: sum of 2 quarters · filed 2023-05-12 | $843.63K derived: sum of 3 quarters · filed 2023-05-12 | $1.04M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $286.26K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $537.09K derived: sum of 2 quarters · filed 2023-03-23 | $728.65K derived: sum of 3 quarters · filed 2023-03-23 | $839.37K 10-K · filed 2023-03-23 |
| 2021-09-30 | $250.82K 10-Q · filed 2022-11-10 | $442.39K derived: sum of 2 quarters · filed 2022-11-10 | $553.11K 10-Q · filed 2022-11-10 | $630.54K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $191.56K 10-Q · filed 2022-08-08 | $302.29K 10-Q · filed 2022-08-08 | $379.71K derived: sum of 3 quarters · filed 2022-08-08 | $383.93K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $110.72K 10-Q · filed 2022-05-16 | $188.15K derived: sum of 2 quarters · filed 2022-05-16 | $192.37K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $77.43K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $81.64K derived: sum of 2 quarters · filed 2022-03-25 | $81.64K 10-K · filed 2022-03-25 | |
| 2020-09-30 | $4.21K 10-Q · filed 2021-11-12 | $4.21K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |